top of page

Government Affairs

The American Psychedelic Practitioners Association is committed to ensuring that our members’ voices are amplified in policy discussions that impact our work as practitioners. 


When APPA publishes documents like our Professional Practice Guidelines for Psychedelic-Assisted Therapy, we make sure that legislators, regulators and other key decision makers have access to them. An important purpose of these consensus documents is to instill confidence that the field is self-organizing, and our work continues to convey that message. 


With the support of The Daschle Group, our strategic counsel in Washington D.C, APPA meets regularly with members of Congress and their staff to discuss the importance of including practitioners in all government-level policies and decisions that will impact clinical practice. We stand strong in our convictions that, while drug companies certainly have a place in the psychedelic ecosystem, there is no substitute for practitioners defining, teaching, and providing good clinical care.


We also provide information and analysis to legislators about pending psychedelic-related legislation, and explain how PAT practitioners will be trained and certified in accordance with APPA-accredited training programs. 


It is often the case that a federal agency or a Congressional committee will request feedback, from the field generally or from APPA specifically, around certain publications, guidelines, or subjects. Any time we submit these official responses, we will post them here for your review.


If you have questions about our government affairs work, please contact Hadas Alterman, our Director of Communications & Policy, at


APPA’s Testimony to the House Committee on Veterans’ Affairs


APPA’s Commentary on Draft FDA Guidance on Psychedelic Research

Hadas Alterman, our Director of Communications & Policy, with Senator Cory Booker, co-sponsor of the Breakthrough Therapies Act. In this discussion, Hadas spoke about the importance of practitioner training and certification in advance of FDA approvals. February 2023, Washington, D.C.

bottom of page